Andra AP fonden Has $14.14 Million Stake in Abbott Laboratories (ABT)

Andra AP fonden lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 20.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 290,900 shares of the healthcare product maker’s stock after selling 75,700 shares during the quarter. Andra AP fonden’s holdings in Abbott Laboratories were worth $14,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. Sanders Morris Harris LLC boosted its stake in shares of Abbott Laboratories by 0.3% during the 2nd quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock worth $242,000 after acquiring an additional 16 shares during the last quarter. St. Louis Trust Co raised its position in shares of Abbott Laboratories by 0.4% during the 2nd quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock valued at $238,000 after purchasing an additional 20 shares during the period. Alpha Windward LLC raised its position in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock valued at $264,000 after purchasing an additional 30 shares during the period. Lakeview Capital Partners LLC raised its position in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock valued at $277,000 after purchasing an additional 33 shares during the period. Finally, Johanson Financial Advisors Inc. raised its position in shares of Abbott Laboratories by 0.5% during the 2nd quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after purchasing an additional 37 shares during the period. Institutional investors and hedge funds own 70.64% of the company’s stock.

Several analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a research report on Tuesday, October 31st. Barclays PLC restated an “overweight” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Citigroup Inc. restated a “neutral” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. BMO Capital Markets restated a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Finally, Cowen and Company set a $68.00 price objective on shares of Abbott Laboratories and gave the company a “buy” rating in a research report on Thursday, October 19th. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Abbott Laboratories has an average rating of “Buy” and an average target price of $56.81.

In related news, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the transaction, the insider now directly owns 221,488 shares of the company’s stock, valued at approximately $10,963,656. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63. Following the transaction, the executive vice president now directly owns 142,082 shares of the company’s stock, valued at $7,986,429.22. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 408,313 shares of company stock worth $21,205,356. Insiders own 0.76% of the company’s stock.

Shares of Abbott Laboratories (NYSE:ABT) opened at $55.30 on Tuesday. Abbott Laboratories has a fifty-two week low of $37.38 and a fifty-two week high of $56.69. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. The firm has a market cap of $95,384.93, a PE ratio of 22.74, a PEG ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. During the same period in the previous year, the firm posted $0.59 EPS. The business’s quarterly revenue was up 28.8% on a year-over-year basis. research analysts anticipate that Abbott Laboratories will post 2.5 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a $0.265 dividend. The ex-dividend date is Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.92%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 83.47%.

TRADEMARK VIOLATION WARNING: This news story was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.truebluetribune.com/2017/11/14/andra-ap-fonden-has-14-14-million-stake-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply